MDxHealth SA MDXH

Healthcare SIC 8071 - Services-Medical Laboratories NAICS Health Care and Social Assistance › Ambulatory Health Care Services › Medical and Diagnostic Laboratories › Medical Laboratories derived Nasdaq

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue $107.9M$90.0M$70.2M$37.1M$22.2M$18.5M$11.8M—
Operating income -$14.4M-$24.7M-$27.3M-$37.9M-$26.8M-$27.1M-$43.2M—
Net income -$33.5M-$38.1M-$43.1M-$44.0M-$29.0M-$28.7M-$43.1M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Total assets $148.0M$157.3M$129.1M$119.1M$75.1M$31.9M——
Total equity -$12.1M$14.8M$7.2M$9.3M$46.9M$5.8M$19.7M$52.1M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-039540.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -50M 0 50M 100M 150M Revenue, FY2019: 11.8M Net income, FY2019: -43.1M Revenue, FY2020: 18.5M Net income, FY2020: -28.7M Revenue, FY2021: 22.2M Net income, FY2021: -29M Revenue, FY2022: 37.1M Net income, FY2022: -44M Revenue, FY2023: 70.2M Net income, FY2023: -43.1M Revenue, FY2024: 90M Net income, FY2024: -38.1M Revenue, FY2025: 107.9M Net income, FY2025: -33.5M FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — $11.8M $18.5M $22.2M $37.1M $70.2M $90.0M $107.9M
Gross profit — — — — — — — —
Net income — -$43.1M -$28.7M -$29.0M -$44.0M -$43.1M -$38.1M -$33.5M

Others in SIC 8071

TickerCompanyMarket capP/ERevenue growth
NTRA Natera, Inc. $58.23B — 35.9%
DGX QUEST DIAGNOSTICS INC $26.70B 27.6x 11.8%
LH LABCORP HOLDINGS INC. $26.68B 31.4x 7.2%
GH Guardant Health, Inc. $22.69B — 32.9%
CAI Caris Life Sciences, Inc. $9.04B — 97.0%
GRAL GRAIL, Inc. $5.92B — 17.2%
RDNT RadNet, Inc. $5.54B — 11.5%
BLLN BillionToOne, Inc. $5.00B 769.8x 100.0%